2-(2-methylnaphthalene-6-yl)propanoic acid | 58460-81-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-(2-methylnaphthalene-6-yl)propanoic acid
• 英文别名: methyl(6-methyl-2-naphthyl)acetate；2-(6-Methylnaphthalen-2-yl)propanoic acid
• CAS: 58460-81-4
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: LJRVHSWMFDDXLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-methylnaphthalene-6-yl)propanoic acid 在 (2S,3S)-2,3-dihydroxy-1,4-bis(hydroxyamino)butane 作用下， 以 乙醇 、 异丙醇 为溶剂， 生成 (S)-2-(2-methylnaphthalene-6-yl)propanoic acid 、 (2R)-2-(6-methylnaphthalen-2-yl)propanoic acid
  参考文献：
  名称：

  Hydrogen-bonding sheets in crystals for chirality recognition: synthesis and application of (2S,3S)-2,3-dihydroxy- and (2S,3S)-2,3-dibenzyloxy-1,4-bis(hydroxyamino)butanes

  摘要：

  Two enantiopure bis(hydroxyamino) compounds were Successfully prepared from dialkyl tartrate by a chiral-pool method and applied as basic resolving agents in the enantioseparation of 2-arylpropanoic acids and arylglycolic acids. (2S,3S)-2,3-Dihydroxy-1,4-bis(hydroxyamino)butane (2S,3S)-1a could moderately recognize the chirality of the 2-arylpropanoic acids, while (2S,3S)-2,3-dibenzyloxy-1,4-bis(hydroxyamino)butane (2S,3S)-1b could not due to the low crystallinity of both the corresponding diastereomeric salts. On the other hand, (2S,3S)-1b showed a similar chirality-recognition ability for the arylglycolic acids. The ability of (2S,3S)-1b was different from those generally observed for widely used primary amine-type resolving agents with regard to the relationship between the resolution efficiency and the similarity in the relative molecular length of a resolving agent and a target racemate. The X-ray crystallographic analyses of the less-soluble diastereomeric salts revealed that in the salts (2S,3S)-1a formed a supramolecular sheet, of which the distance was variable to make the resultant dissymmetric space fit to the shape of the target acids, and that (2S,3S)-1b was constructed from a robust supramolecular sheet, consisting of hydrogen-bonding 21 columns, with the participation of the hydroxy group of the arylglycolic acids. These X-ray crystallographic analyses also suggested that for the formation of a supramolecular sheet, the coexistence of two hydroxyamino groups is essential. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.11.006
• 作为产物：
  描述：

  benzhydryl 2-(2-methoxynaphthalen-6-yl)propanoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 1.25h， 生成 2-(2-methylnaphthalene-6-yl)propanoic acid
  参考文献：
  名称：

  Convenient Formation of Diphenylmethyl Esters Using Diphenylmethyl Trichloroacetimidate

  摘要：

  Diphenylmethyl trichloroacetimidate is a useful reagent for the protection of carboxylic acids as their corresponding diphenylmethyl esters. These esterifications proceed rapidly without the need for an added catalyst or promoter. A variety of carboxylic acid substrates undergo esterification in excellent yields with the trichloroacetimidate reagent, including substrates possessing acid- or base-sensitive functionality. Protection of a carboxylic acid with a highly enolizable alpha-stereocenter using diphenylmethyl imidate was also accomplished without racemization.

  DOI：

  10.1055/s-0033-1340293

文献信息

• Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
  申请人：Bezwada Rao S.

  公开号：US20120035259A1

  公开（公告）日：2012-02-09

  The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.

  本发明提供了一氧化氮(NO)和可选的药物释放的大分子和寡聚物，其中药物分子和一氧化氮释放部分通过可吸收的大分子或可水解降解的寡聚物链连接，并且大分子或寡聚物由来自诸如乙醇酸、乳酸、己内酰胺和对二恶烷等安全且生物相容的分子的重复单元组成。此外，本发明还涉及从一氧化氮和/或药物分子释放的大分子或寡聚物控制释放一氧化氮(NO)。此外，本发明还涉及包含本发明的一氧化氮和药物释放大分子和寡聚物的医疗器械、医疗器械涂层和治疗方法。
• ABSORBABLE BRANCHED POLYESTERS AND POLYURETHANES
  申请人：Bezwada Biomedical, LLC

  公开号：US20140142199A1

  公开（公告）日：2014-05-22

  The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.

  本发明涉及一种新型可水解异氰酸酯、可水解支链多元醇及其制备的支链可吸收聚酯和聚氨酯的发现。由此得到的可吸收聚合物可用于药物输送、支架、高孔隙率泡沫、网状泡沫、组织工程、组织粘合剂、防止粘连、骨蜡制剂、医疗设备涂层、表面改性剂以及其他可植入医疗设备。此外，这些可吸收聚合物可以具有受控的水解降解特性。
• PYRAZOLOPYRIMIDINE COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20150239889A1

  公开（公告）日：2015-08-27

  Provided is a pyrazolopyrimidine compound represented by formula (I) having an HIF-PHD inhibitory effect, or a pharmaceutically acceptable salt thereof. [In the formula, represents an optionally substituted 7-hydroxypyrazolo[4,3-d]pyrimidine-5-yl, X represents a simple bond or an optionally substituted straight-chain alkylene, Z represents hydrogen atom, or formula (i), formula (ii) or formula (iii) and rings A and A′ are independently an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted alicyclic hydrocarbon, or an optionally substituted non-aromatic heterocycle.]

  提供的是一种具有HIF-PHD抑制效果的吡唑并嘧啶化合物，其由公式（I）表示，或其药用可接受的盐。[在公式中，代表一个可选地取代的7-羟基吡唑并[4,3-d]嘧啶-5-基，X代表一个简单键或一个可选地取代的直链亚烷基，Z代表氢原子，或公式（i），公式（ii）或公式（iii）和环A和A'分别独立地代表一个可选地取代的芳香族，一个可选地取代的杂芳族，一个可选地取代的脂肪环烃，或一个可选地取代的非芳香族杂环]。
• PROCESS FOR SYNTHESIZING PHENYLACETIC ACID BY CARBONYLATION OF TOLUENE
  申请人：Physics, Chinese Academy of Sciences Lanzhou Institute of Chemical

  公开号：US20130303798A1

  公开（公告）日：2013-11-14

  A production process for substituted phenylacetic acids or ester analogues thereof is disclosed. In this process toluene or toluene substituted with various substituents, an alcohol, an oxidant and carbon monoxide are used as raw materials to obtain compounds comprising structure of phenylacetic acid ester or analogues thereof by catalysis of the complex catalyst formed from transition metal and ligand, and such compounds are hydrolyzed to obtain various substituted phenylacetic acid based compounds. This type of compounds and their derivatives serve as important fine chemicals used widely in the industries of pharmaceuticals, pesticides, perfume and the like.

  揭示了一种用于取代苯乙酸或其酯类似物的生产工艺。在这个工艺中，甲苯或带有各种取代基的甲苯、醇、氧化剂和一氧化碳被用作原料，通过过渡金属和配体形成的复合催化剂的催化作用，获得包含苯乙酸酯结构或其类似物的化合物，并且这些化合物被水解以获得各种基于取代苯乙酸的化合物。这类化合物及其衍生物在制药、农药、香水等行业中被广泛应用，作为重要的精细化学品。
• Drug Delivery of a Cox Inhibitor from Embolic Agents
  申请人：Lewis Lennard Andrew

  公开号：US20070281028A1

  公开（公告）日：2007-12-06

  A pharmaceutical composition for malignant tumour embolisation comprises a polymer and, associated with the polymer in a releasable form, a COX inhibitor, e.g. a non-steroidal anti inflammatory drug, such as ibuprofen. The polymer is preferably-in particulate form, such as in the form of microspheres. A suitable polymer is a crosslinked polyvinyl alcohol polymer formed by the copolymerisation of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of malignant tumours, leading to tumour necrosis or ischaemia, with anti-angiogenic effects, promotion of apoptosis, decrease in invasiveness of tumour cells and resultant tumour regression.

  一种用于恶性肿瘤栓塞的制剂，包括聚合物和与聚合物以可释放形式相关联的COX抑制剂，例如非甾体抗炎药物，如布洛芬。聚合物最好是以微粒形式，例如微球形式。适用的聚合物是交联聚乙烯醇聚合物，通过PVA大分子与其他乙烯基不饱和单体的共聚形成。该制剂提供了一种协同治疗恶性肿瘤症状的方法，导致肿瘤坏死或缺血，具有抗血管生成作用，促进凋亡，减少肿瘤细胞的侵袭性和导致肿瘤退化。